Disease relevance of 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• Double-blind crossover trial of bisolvon in the treatment of chronic bronchitis [1].
• In a double blind randomised trial of 95 children aged 3-8 years with otitis media with effusion (OME), the efficacy of the mucolytic agent bromhexine hydrochloride (Bisolvon) was compared with a placebo [2].

High impact information on 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• The absorption of bromhexine from Bromhexin tablets 8 mg, DAK has been compared with that from Bisolvon tablets 8 mg, Boehringer Ingelheim, in a two-way complete crossover study [3].
• The effect of an intravenous expectorant agent, i.e. Bisolvon, on the secretory activity of the tracheal mucosa of the dog was studied with the scanning electron microscope [4].
• The rapid secretory response to the expectorant, Bisolvon, confirmed the active and important role of the tracheal mucociliary clearance mechanism for the protection of the lower respiratory tract [4].

Chemical compound and disease context of 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• The results of a double-blind crossover trial of bromhexine (Bisolvon) in the treatment of chronic bronchitis are reported [5].

Anatomical context of 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• A review of the literature together with the results of this trial suggest that, when adequate consideration is given to a number of therapeutic variables, Bisolvon will be effective medication for most patients with chronic bronchitis associated with thick, tenacious sputum [5].

Gene context of 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• It is concluded that Bromhexin, DAK and Bisolvon are bioequivalent [3].

Analytical, diagnostic and therapeutic context of 2-(1-amino-1-cyclohexyl-ethyl)-4,6-dibromo-aniline

• After the oral administration of Bisolvon Griblettes corresponding to 30 mg codeine phosphate to seven subjects maximum codeine concentrations were obtained after 1-2 h and codeine remained detectable generally 24 h post dosing [6].

References